Postmenopausal hormone therapy and the risk of cardiovascular disease

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2041-2053

  Bittner, Vera ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cardiovascular disease; Hormone therapy; Menopause; Women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGESTERONE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ARTERIAL WALL THICKNESS; ARTERY DISEASE; ARTERY INTIMA PROLIFERATION; BRAIN HEMORRHAGE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART REINFARCTION; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; PATIENT COMPLIANCE; POSTMENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; CAROTID ARTERIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 68949152715     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903066829     Document Type: Review

References (84)

1. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-501 Current US guidelines for the prevention of cardiovascular disease in women. (Pubitemid 46648385)
2. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27:994-1005
3. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion 420 November 2008: hormone therapy and heart disease. Obstet Gynecol 2008;112:1189-1192
4. Utian WH, Archer DF, Bachmann GA, et al.; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008;15:584-602
5. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028-2040 (Pubitemid 47579557)
6. Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2008;90(Suppl 3):S88-102
7. American Association of Clinical Endocrinologists Reproductive Medicine Committee. Position Statement on Hormone Replacement Therapy (HRT) and Cardiovascular Risk. The First Messenger 2008; January/February: page 6. Also Available from: http://www.aace.com/pub/pdf/guidelines/HRTCVRISKposition- statement.pdf [Last accessed 16 March 2009]
8. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7 Excellent review of genomic and nongenomic vascular effects of exogenous hormones. The authors postulate that the beneficial cardiovascular effects of hormone therapy after menopause only accrues, if such therapy is given before advanced atherosclerosis develops.
9. Miller AP, Xing D, Feng W, etal. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007;14:251-60 Animal data that support the timing hypothesis. (Pubitemid 46673477)
10. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-84 Animal data that support the timing hypothesis.
11. Stampfer MJ, Coldlitz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
12. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037
13. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72 (Pubitemid 28279924)
14. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84 Meta-analysis that shows confounding of observational hormone data by socioeconomic status and other participant characteristics.
15. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. Scientific Review. JAMA 2002;288:872-881
16. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650 (Pubitemid 36204960)
17. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231 (Pubitemid 351809317)
18. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 2001;38:243-261
19. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208
20. Shlipak MG, Chaput LA, Vittinghoff E, et al.; for the Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003;146:870-875
21. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-1852
22. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-12 Main outcomes paper of the Women's Health Initiative (WHI) estrogen trial.
23. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33 Main outcomes paper of the Women's Health Initiative estrogen plus progestin trial.
24. Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 2001;37:425-430 (Pubitemid 32147248)
25. Hsia J, Otvos JD, Rossouw JE, et al. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative Hormone Trials. Arterioscler Thromb Vasc Biol 2008;28:1666-1671
26. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
27. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative Trials of Hormone Therapy. Arch Intern Med 2008;168:2245-2253
28. Koh KK, Yoon BK. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22-30
29. Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005;8:317-326 (Pubitemid 41617480)
30. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system. Lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-1753
31. Vigen C, Hodis HN, Chandler WL, et al. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis. J Thromb Haemost 2007;5:1201-1208 (Pubitemid 46902123)
32. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-268 (Pubitemid 32125376)
33. Byington RP, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692-1697
34. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953
35. Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995;142:1011-1019
36. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529 (Pubitemid 30650747)
37. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440 (Pubitemid 35340539)
38. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-545 (Pubitemid 36951365)
39. Ouyang P, Tardif JC, Herrington DM, et al.; for the EAGAR investigators. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis 2006;189:375-386
40. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613 First large randomized trial of hormone therapy indicating that hormone therapy may not result in cardiovascular benefit as previously assumed. (Pubitemid 28502636)
41. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57 (Pubitemid 34705518)
42. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study. Lessons learned. Circulation 2002;105:917-922 Summarizes subgroup results in the HERS study. Also discusses pros and cons of multiple subgroup testing in general and how to interpret such subgroup analyses. (Pubitemid 34184567)
43. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-642
44. Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease. The Heart and Estrogen/Progestin Replacement Study. Circulation 2000;102:2228-2232
45. Grady D, Wenger NK, Herrington DM, et al. for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-696
46. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22:1012-1017 (Pubitemid 34655232)
47. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-1062 (Pubitemid 35279139)
48. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-1249 (Pubitemid 34951488)
49. Hsia J, Langer RD, Manson JAE, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006;166:357-365
50. Manson JAE, Allison MA, Rossouw JE, et al.; for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602
51. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434 (Pubitemid 43948050)
52. Hsia J, Criqui MH, Herrington DM, et al. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am Heart J 2006;152:170-176 (Pubitemid 43974720)
53. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-780
54. Manson JAE, Hsia J, Johnson KC, et al.; for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
55. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al.; for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684
56. Cushman M, Kuller LH, Prentice R, et al.; for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580
57. Rossouw JE, Prentice RL, Manson JAE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477 Analysis of WHI results by age and time since last menstrual period. Although interpreted cautiously by the WHI investigators, this paper has renewed enthusiasm for postmenopausal hormone therapy early after menopause.
58. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239;doi:10.1136/ bmj.39266.425069.AD (Pubitemid 47262422)
59. The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-2008 Only randomized trial among postmenopausal women until now that has evaluated estradiol monotherapy in relation to cardiovascular end points.
60. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006;113:5-14
61. Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005;330:342; doi:10.1136/bmj.38331. 655347.8F
62. Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031-41 Recent meta-analysis that also provides age-specific estimates and does not find a statistically significant benefit on coronary heart disease (CHD) events in younger women.
63. Salpeter SR, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women. A meta-analysis. J Gen Intern Med 2004;19:791-804 Meta-analysis that is widely cited as supporting evidence for benefit of hormone therapy among healthy younger postmenopausal women, even though the majority of deaths in this mortality analysis occurred in a trial of hormone therapy among ovarian cancer survivors [65]. (Pubitemid 38951954)
64. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-6 Methodologically problematic meta-analysis of CHD events which concludes that there is benefit on CHD events among younger postmenopausal women.
65. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors. A randomized controlled trial. Cancer 1999;86:1013-1018
66. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention study. Climacteric 2005;8:3-12 (Pubitemid 40675116)
67. Hodis HN. ELITE trial: Early versus Late Intervention with Estradiol. Available from: www.clinicaltrials.gov/show/NCT00114517 [Last accessed 15 March 2009]
68. Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-221 Primate data that indicate an adverse impact of medroxy progesterone acetate (MPA) on vascular protective effects of estrogen previously shown in this model.
69. Behavioral Risk Factor Surveillance System - Web Enabled Analysis Tool. Available from: http://apps.nccd.cdc.gov/s-broker/htmsql.exe/weat/Select-Year. hsql?Analysis=freq&Title=Cross%20Tabulation [Last accessed 19 March 2009]
70. Stefanick ML, Cochrane BB, Hsia J, et al. The Women's Health Initiative Postmenopausal Hormone Trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:S78-86 (Pubitemid 37324177)
71. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care 2004;27:2444-2449 Analysis from the National Health and Nutrition Examination Survey (NHANES), which indicates that prevalence of metabolic syndrome and thus cardiovascular risk is increasing in middle-aged women.
72. Salpeter SR, Buckley NS, Liu H, et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42-52 Cost-effectiveness analysis that suggests that hormone therapy initiated at or near the time of menopause and continued for up to 30 years may be cost-effective.
73. Hutton JD, Jacobs HS, Murray MA, James VH. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1978;1:678-681 (Pubitemid 8297037)
74. Gast GCM, Grobbee DE, Pop VJM, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492-8 Study demonstrates in a community-based sample that women aged 46-57 years with vasomotor symptoms have higher cardiovascular risk factor prevalence than women without such symptoms.
75. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-193 The investigators found high rates of recurrence of vasomotor symptoms after cessation of hormone therapy, suggesting that a strategy of short-term therapy in younger women will not be successful in controlling vasomotor symptoms in a substantial proportion of postmenopausal women.
76. Kok HS, van Asselt KM, vander Schouw YT, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006;47:1976-1983 Provocative paper that suggests that heart disease risk determines menopausal age.
77. Depypere HT, Tummers P, De Bacquer D, et al. Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. Climacteric 2007;10:238-43 Analysis that suggests that large-scale morbidity/mortality trials of postmenopausal hormone therapy among young postmenopausal women are not feasible. (Pubitemid 46752442)
78. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy. Findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012-18 This analysis shows that a benign cardiovascular risk factor profile in middle-age is associated with excellent prognosis.
79. Daviglus ML, Liu K, Pirzada A, et al. Favorable cardiovascular risk profile in middle age and health-related quality of life in older age. Arch Intern Med 2003;163:2460-8 Analysis shows that a benign cardiovascular risk profile in middle-age is associated with improved quality of life in older age. Reference [78] and this one suggest that emphasis on primordial primary prevention throughout a woman's lifetime is likely to be a better strategy reduction of cardiovascular risk in the postmenopausal years than hormone therapy started at the time of menopause. (Pubitemid 37385788)
80. Chlebowski RR, Hendrix SL, Langer et al.; for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253
81. Ritenbaugh C, Stanford JL, Wu LL, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative Randomized Clinical Trial. Cancer Epidemiol Biomarkers Prev 2008;17:2609-2618
82. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C: for the Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
83. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al: for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Trial. J Bone Miner Res 2006;21:817-828 (Pubitemid 43787988)
84. Cauley JA, Robbins J, Chen Z, et al: for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA 2003;290:1729-1738